This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
Eleven days. That is how long it took between management telling us the IBSRELA miss was a payer-access problem and the executive who owns payer access filing his exit.
Today’s 8-K discloses that Eric Foster notified Ardelyx on August 11, 2026 of his decision to resign as Chief Commercial Officer, effective August 28, 2026. The filing says he left “to pursue a new opportunity with a pre-commercial company,” and that the resignation “is not a result of any disagreement with the Company.” The stock has gone from $4.87 on the day of the Q2 print to $4.06 today — down 16.6% in under two weeks, and roughly 35% off the ~$6.28 April reference in the original deep dive.
The Receipts
The departure. CCO resigns August 11, effective August 28. A 17-day runway between notice and exit — short, and no successor named in the filing. No interim appointment disclosed, no transition plan, no retention package.
The stated reason. A move to a pre-commercial company. That is the detail worth sitting with. A commercial chief at a company doing $118.1M in quarterly product revenue leaving for an organization with no product on the market is a career move toward equity upside and away from an execution seat that just got harder.
The boilerplate. “Not a result of any disagreement with the Company” is standard Item 5.02 language and appears in virtually every voluntary-resignation 8-K. It is neither a red flag nor a reassurance — it’s a form field.
The timing. Q2 was reported August 6. Notice came August 11. The 8-K was signed August 17.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.